Weight Watchers Debuts Med+ GLP-1 Program Via LillyDirect to Expand National Access
WW•Weight Watchers is now accessible via Eli Lilly’s LillyDirect digital platform, connecting customers to its Med+ program offering integrated GLP-1 medications and behavioral support nationwide. The expanded access aims to boost Med+ enrollment and drive revenue growth by pairing FDA-approved treatments with Weight Watchers’ six-decade clinical and community support model.
1. Partnership Launch and Scope
On June 4, WW International partnered with Eli Lilly’s LillyDirect platform to connect customers to its Med+ weight management program. This integration enables patients nationwide to access Weight Watchers’ integrated GLP-1 medication care model directly through LillyDirect’s digital healthcare ecosystem.
2. Med+ Program Features
Weight Watchers Med+ combines FDA-approved GLP-1 prescriptions with licensed clinical care, nutrition guidance, community support and the embedded GLP-1 Success program. The model is designed to support patients before, during and after medication use, leveraging six decades of Weight Watchers’ behavioral science expertise.
3. Distribution and Customer Reach
LillyDirect users can now seamlessly enroll in Med+, access pharmacy fulfillment resources and educational materials. This partnership broadens Weight Watchers’ clinical offering and taps into LillyDirect’s growing user base as demand for GLP-1 therapies rises.
4. Financial and Strategic Impact
By expanding access, Weight Watchers expects to drive higher Med+ enrollments and recurring subscription revenue, supporting long-term growth. The move strengthens Weight Watchers’ position in the obesity care market and aligns with its strategy to pair medication with comprehensive support.
